These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8141564)

  • 1. Effect of mycophenolic acid on Epstein-Barr virus infection of human B lymphocytes.
    Alfieri C; Allison AC; Kieff E
    Antimicrob Agents Chemother; 1994 Jan; 38(1):126-9. PubMed ID: 8141564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
    Tanner JE; Menezes J
    Blood; 1994 Dec; 84(11):3956-64. PubMed ID: 7949151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
    Tanner JE; Alfieri C
    Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus in B lymphocytes: viral gene expression and function in latency.
    Rogers RP; Strominger JL; Speck SH
    Adv Cancer Res; 1992; 58():1-26. PubMed ID: 1312289
    [No Abstract]   [Full Text] [Related]  

  • 6. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.
    Huang S; Stupack D; Mathias P; Wang Y; Nemerow G
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8156-61. PubMed ID: 9223331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus.
    Chisari FV; Curtiss LK; Jensen FC
    J Clin Invest; 1981 Aug; 68(2):329-36. PubMed ID: 6267100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells.
    Bende RJ; Jochems GJ; Frame TH; Klein MR; van Eijk RV; van Lier RA; Zeijlemaker WP
    Cell Immunol; 1992 Sep; 143(2):310-23. PubMed ID: 1324802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing faces of EBV research.
    Klein G; Klein E
    Prog Med Virol; 1984; 30():87-106. PubMed ID: 6087416
    [No Abstract]   [Full Text] [Related]  

  • 10. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
    Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
    Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
    Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
    Robertson ES; Tomkinson B; Kieff E
    J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
    J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune surveillance against Epstein-Barr virus.
    Moss DJ; Burrows SR; Khanna R; Misko IS; Sculley TB
    Semin Immunol; 1992 Apr; 4(2):97-104. PubMed ID: 1377517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.
    Aguirre AJ; Robertson ES
    J Virol; 2000 Jan; 74(2):735-43. PubMed ID: 10623735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for Epstein-Barr virus induced pathogenesis and disease.
    Sample C; Kieff E
    Springer Semin Immunopathol; 1991; 13(2):133-46. PubMed ID: 1664982
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuramide inhibits Epstein-Barr virus-induced transformation activity and proliferation of transformed B lymphocytes.
    Venanzoni MC; Angeloni A; Di Muzio M; Faggioni A; Frati L
    Antiviral Res; 1997 Feb; 33(3):177-85. PubMed ID: 9037374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
    Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
    J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.
    Straus SE; Cohen JI; Tosato G; Meier J
    Ann Intern Med; 1993 Jan; 118(1):45-58. PubMed ID: 8380053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.